Reporting

To inform on the prescribing of tirzepatide (Mounjaro®) in primary care settings and the management of patients, ICBs in England are mandated under the NHS Standard Contract to provide information in a standardised format. The table below specifies the reporting schedule.

Data should only be submitted for the stipulated reporting period and not cumulative.

Table 1 reporting schedule

Every ICB in England has submitted details of two nominated reporters to NHS England. These nominated reporters will have access to the Data Collections Framework to submit their ICBs aggregated data in relation to the prescribing of tirzepatide (Mounjaro®) in primary care settings.

The link to the reporting framework has been shared with the nominated reporters at the ICB. If you believe you should be a nominated reporter with access to the platform, please contact your ICBs Single Point of Contact for the prescribing of tirzepatide in primary care to submit a request to the NHS England National Obesity Team.

To support informed decision making regarding future financial allocations, NHS England expects ICBs to provide quarterly reports on the delivery of the NICE Funding Variation for tirzepatide (Mounjaro®). These reports should include detailed observations on patient access and prescribing practices. This approach ensures that the NICE funding variation of tirzepatide is monitored effectively.

The quarterly reports include the following indicators, with Section 3 providing the definitions and associated SNOMED codes necessary for accurate reporting:

1. Number of patients assessed for eligibility of tirzepatide (Mounjaro®) in primary care settings for the management of obesity.
2. Number of patients prescribed tirzepatide (Mounjaro®) in primary care settings for the management of obesity.
3. Number of patients referred to the national wrap around care service (named behavioural support for obesity prescribing in the interim by service providers).
4. Number of patients referred to the local wrap around care.
5. Number of patients who have declined tirzepatide (Mounjaro®) in primary care settings for the management of obesity.
6. Number of patients who have stopped tirzepatide (Mounjaro®) in primary care settings for the management of obesity.

The reporting framework requests above information broken down by:

1. Ethnic background (Asian, Black, Mixed, Other, White, unknown). 
2. Quintiles of deprivation: NHSE DCF template uses Quintiles of Deprivation (IMD 1 to IMD 5, where IMD 1 is the most deprived and IMD 5 is the least deprived). IMD 1 to IMD 10 are Deciles are deprivation. For more information visit Public Health Technical Guidance – Using the English indices of deprivation and English indices of deprivation 2019 - GOV.UK. 
3. Sex: The sex the patient is registered as with their general practice. 
4. Severe Mental Illness (SMI): A diagnosis of schizophrenia, bipolar affective disorder or who have experienced an episode of non-organic psychosis.
5. Learning Disability (LD): A formally recorded diagnosis of a learning disability. This is different to a learning difficulty, which is a type of special educational need, such as dyslexia, or other condition which affects only one area of learning (such as reading, writing, spelling or maths) 
6. Delivery model: This is applicable to those ICBs who have opted for more than one delivery model. Most ICBs will only need to report under one delivery model for this section. The inclusion of “Custom Model” for reporting is for those ICBs who have truly opted under a model that does not align with any of the other standard models outlined previously.

Through systematic reporting on these indicators, NHS England aims to monitor the prescribing of tirzepatide (Mounjaro®) for the management of obesity and understand: